Introducing an innovative approach to smoking cessation, our project combines the latest in digital therapeutic apps with cutting-edge inhaler technology. Developed through a collaboration between Curb and an a novel smoking cessation device, this initiative aims to transform the way individuals overcome smoking addiction. By harnessing data-driven insights and predictive technology, we're creating personalised support tools to effectively help smokers quit. This project is not just about developing a product; it's about advancing public health and offering a new, more effective solution to combat one of the leading causes of preventable diseases worldwide.

Mind Health AI is a platform with a mission to alleviate the mental burden from people trying to make healthier choices. We intend to achieve this by building first-of-its-kind predictive technology that recognises behaviour around craving or risk, and then delivering therapeutic interventions to support people through those moments. Our products are prescription digital therapeutics, the first condition we are working on is alcohol, with technology that will predict and prevent relapse in problem drinkers. This project will enable us to work with regulatory advisors to prepare our product to pass the assessment criteria the NHS requires from its commercial partners.

Mind Health AI is a digital therapeutics start up, making cutting-edge science and technology accessible to both consumers and clinicians. We support individuals who want to change harmful behaviours and self--manage chronic health conditions, via predictive models generated by machine learning. We have a diverse, UK-based founding team with expertise in clinical, commercial and technical domains. Our combined professional experience provides a wealth of relationships, with realistic routes to market and institutional investment, and real potential for scaling. Our first product is alma, a mobile application which helps users beat cravings and quit drinking. Alcohol consumption is linked as a causal factor to more than 60 diseases, but although a range of interventions has been available for decades, the parlous state of care for alcohol dependency means that 90% of people who go through rehab relapse within five years. On this specific project, we seek to recruit users, building a dataset large enough to inform algorithms that can predict negative health outcomes, including cravings, lapse, full relapse and service disengagement. We are working with academics at the global forefront of their fields in behavioural science, predictive models and digital therapeutics. The value proposition of our product has been validated by stakeholder groups, including people seeking to quit drinking, as well as clinicians and professionals in related industries such as insurance and pharmaceuticals.